Translational Session

The Revolution Is Here: New Treatments for Diabetes and Kidney Diseases, Including the Barry M. Brenner, MD, Endowed Lectureship

November 07, 2019 | 10:30 AM - 12:30 PM

Location: Ballroom C, Walter E. Washington Convention Center

Session Description

Experts in the fields of nephrology and diabetology review emerging data about underlying biological mechanisms of complications and key clinical trials of newer glucose-lowering agents. The session provides the most current evidence and recommendations for preventing the kidney and cardiovascular complications of both type 1 and type 2 diabetes. The educational content is designed for an audience of both clinicians and scientists.

ASN gratefully acknowledges Monarch Pharmaceuticals for support of the Barry M. Brenner, MD, Endowed Lectureship.

ASN thanks the American Diabetes Association for assistance with this session.

Support is provided by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.

Learning Objective(s)

  • Integrate structural assessment to advance knowledge and treatment of diabetic kidney disease (DKD)
  • Compare the key clinical trials of newer glucose-lowering agents that investigated CVD and DKD outcomes in diabetes
  • Describe application of newer glucose-lowering agents to individualize treatments

Learning Pathway(s)

  • Diabetes and Metabolism
  • Chronic Kidney Disease


  • Adeera Levin, MD
  • Susanne B. Nicholas, MD, PhD, MPH